Cite
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
MLA
Samaniego, Felipe, et al. “90Y-Ibritumomab Tiuxetan Radiotherapy as First-Line Therapy for Early Stage Low-Grade B-Cell Lymphomas, Including Bulky Disease.” British Journal of Haematology, vol. 166, no. 1, July 2014, pp. 1–7. EBSCOhost, https://doi.org/10.1111/bjh.13021.
APA
Samaniego, F., Berkova, Z., Romaguera, J. E., Fowler, N., Fanale, M. A., Pro, B., Shah, J. J., McLaughlin, P., Sehgal, L., Selvaraj, V., Braun, F. K., Mathur, R., Lei Feng, Neelapu, S. S., & Kwak, L. W. (2014). 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. British Journal of Haematology, 166(1), 1–7. https://doi.org/10.1111/bjh.13021
Chicago
Samaniego, Felipe, Zuzana Berkova, Jorge E. Romaguera, Nathan Fowler, Michelle A. Fanale, Barbara Pro, Jatin J. Shah, et al. 2014. “90Y-Ibritumomab Tiuxetan Radiotherapy as First-Line Therapy for Early Stage Low-Grade B-Cell Lymphomas, Including Bulky Disease.” British Journal of Haematology 166 (1): 1–7. doi:10.1111/bjh.13021.